Menotrophin Ferring-Léciva (Menotrophin)

The product contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After subcutaneous injection, FSH binds to receptors on granulosa cells to promote follicle growth and estrogen production, while LH activates theca‑cell receptors to support androgen synthesis and triggers the LH surge that leads to ovulation.

The exact dose and treatment schedule are individualized and set by the prescribing physician based on the patient’s ovarian response, underlying diagnosis, and the specific assisted‑reproduction protocol being used. No standard dosing can be provided without a medical assessment.

Menotrophin is intended for use before conception and is contraindicated once pregnancy is confirmed. Limited safety data are available for breastfeeding, and the drug is generally not recommended during lactation unless the benefit outweighs potential risk as assessed by a healthcare professional.

Enquiries are submitted via the product page on gnhindia.com. Provide the required quantity and institutional credentials; GNH India then contacts the buyer to confirm trade or procurement details, pricing, availability, shipping conditions (including cold‑chain if required) and any necessary import documentation.

Menotrophin is a combined FSH/LH preparation, whereas some alternatives contain only FSH (e.g., recombinant FSH) or only LH. The combined formulation can simplify dosing for protocols that require both hormones, but clinicians may choose a single‑component product based on individual patient response or specific protocol requirements.

Menotrophin must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Vials should be kept in their original packaging until use and discarded after the recommended in‑use period once removed from refrigeration.

The medication is given by subcutaneous injection, typically into the abdomen or thigh. Healthcare professionals should follow aseptic technique, use the appropriate needle size, and rotate injection sites to minimise local irritation. Patients should be trained on self‑administration if required by the treatment plan.

The most serious adverse events include ovarian hyperstimulation syndrome (OHSS), which can be severe and require hospitalisation, multiple pregnancy, thromboembolic complications, and severe allergic reactions such as anaphylaxis. Prompt medical evaluation is essential if any of these signs appear.

Menotrophin is contraindicated in women who are already pregnant, have known hypersensitivity to any component of the formulation, or have uncontrolled thyroid disease, active ovarian cysts, or severe ovarian failure where stimulation would be ineffective. A thorough medical assessment is required before initiating therapy.